Background Atopic dermatitis (AD) is a common chronic inflammatory skin disease in children, often preceding or coexisting with other atopic conditions. Severe AD significantly impacts quality of life and is associated with mental health disorders and sleep disturbances. Dupilumab is approved for moderate‐to‐severe AD in children aged 6 months and older. However, limited studies have evaluated its efficacy in diverse populations, especially in Latin American children. Methods We conducted a multicenter, retrospective study in Colombia, including children aged ≤ 18 years with moderate‐to‐severe AD who began dupilumab treatment between January 1, 2018, and January 1, 2024. Data collected included demographics, disease characteristics, treatment history, adverse events (AEs), and disease severity scores. Statistical analyses were performed using R software ( p < 0.05). Results Ninety‐two patients were included, with a median age of 14 years at dupilumab initiation. The most common comorbidities were allergic rhinitis (75%) and asthma (34%). Significant improvements in disease severity were observed, with a median reduction of 72% in EASI and 55% in SCORAD between Weeks 10 and 22, and 81% and 69%, respectively, by Weeks 46–58. Ocular AEs were the most frequent (23%), and paradoxical head and neck dermatitis occurred in 15% of patients. No serious AEs were reported, and 94% of patients remained on treatment. Conclusions Dupilumab showed significant clinical improvements in Latin American children with moderate‐to‐severe AD. AEs were mild and transient. These findings underscore the need for evaluating dupilumab’s efficacy in diverse populations for personalized treatment strategies.
Ordóñez et al. (Thu,) studied this question.